UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 102

Sortiert nach

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

The New England journal of medicine, 2016-07, Vol.375 (4), p.345-356

2016

Volltextzugriff (PDF)

Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis

Journal of the American Academy of Dermatology, 2016-07, Vol.75 (1), p.83-98.e4

2016

Volltextzugriff (PDF)

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

Journal of the American Academy of Dermatology, 2015-07, Vol.73 (1), p.37-49

2015

Volltextzugriff (PDF)

Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis

Journal of allergy and clinical immunology, 2014-04, Vol.133 (4), p.1032-1040

2014

Volltextzugriff (PDF)

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

The Lancet (British edition), 2008-05, Vol.371 (9625), p.1665-1674

2008

Volltextzugriff (PDF)

Guidelines of care for the management of psoriasis and psoriatic arthritis

Journal of the American Academy of Dermatology, 2011-07, Vol.65 (1), p.137-174

2011

Volltextzugriff (PDF)

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

Journal of the American Academy of Dermatology, 2008, Vol.58 (1), p.106-115

2008

Volltextzugriff (PDF)

A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis

Journal of the American Academy of Dermatology, 2014-12, Vol.71 (6), p.1176-1182

2014

Volltextzugriff (PDF)

Humanized anti–IFN-γ (HuZAF) in the treatment of psoriasis

Journal of allergy and clinical immunology, 2015-02, Vol.135 (2), p.553-556.e3

2015

Volltextzugriff (PDF)

Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis

Journal of the American Academy of Dermatology, 2010-09, Vol.63 (3), p.448-456

2010

Volltextzugriff (PDF)

Research gaps in psoriasis: Opportunities for future studies

Journal of the American Academy of Dermatology, 2014-01, Vol.70 (1), p.146-167

2014

Volltextzugriff (PDF)

Integrated safety analysis: Short- and long-term safety profiles of etanercept in patients with psoriasis

Journal of the American Academy of Dermatology, 2012-08, Vol.67 (2), p.245-256

2012

Volltextzugriff (PDF)

Clinical Goals and Barriers to Effective Psoriasis Care

Dermatology and therapy, 2019-03, Vol.9 (1), p.5-18

2019

Volltextzugriff (PDF)

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics

Journal of the American Academy of Dermatology, 2019-04, Vol.80 (4), p.1029-1072

2019

Volltextzugriff (PDF)

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)

Journal of the American Academy of Dermatology, 2018-08, Vol.79 (2), p.302-314.e6

2018

Volltextzugriff (PDF)

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities

Journal of the American Academy of Dermatology, 2019-04, Vol.80 (4), p.1073-1113

2019

Volltextzugriff (PDF)

Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies

Journal of the American Academy of Dermatology, 2020-06, Vol.82 (6), p.1445-1486

2020

Volltextzugriff (PDF)

Wolf’s isotopic response of lichen planus following contact dermatitis

JAAD Case Reports, 2022-09, Vol.27, p.128-130

2022

Volltextzugriff (PDF)

Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy

Journal of the American Academy of Dermatology, 2019-09, Vol.81 (3), p.775-804

2019

Volltextzugriff (PDF)

Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients

Journal of the American Academy of Dermatology, 2020-01, Vol.82 (1), p.161-201

2020

Volltextzugriff (PDF)

Guidelines of care for the management of psoriasis and psoriatic arthritis Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics

Journal of the American Academy of Dermatology, 2008-05, Vol.58 (5), p.826-850

2008

Volltextzugriff (PDF)

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions

Journal of the American Academy of Dermatology, 2011-07, Vol.65 (1), p.137-174

2011

Volltextzugriff (PDF)

Guidelines of care for the management of psoriasis and psoriatic arthritis Section 2. Psoriatic arthritis : Overview and guidelines of care for treatment with an emphasis on the biologics

Journal of the American Academy of Dermatology, 2008-05, Vol.58 (5), p.851-864

2008

Volltextzugriff (PDF)

Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis

Advances in therapy, 2022-05, Vol.39 (5), p.2256-2269

2022

Volltextzugriff (PDF)

1 – 25 von 102

Suche als RSS-Feed

Aktive Filter

KollektionTaylor & Francis:Master (3349 titles)

Nur zeigenMit Volltextzugriff

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(98)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(68)
Dermatology
(65)
Life Sciences & Biomedicine
(65)
Humans
(59)
Psoriasis - Drug Therapy
(36)
Psoriasis
(35)
Biological And Medical Sciences
(34)
Medical Sciences
(34)
Female
(32)
Male
(31)
Middle Aged
(27)
Psoriasis. Parapsoriasis. Lichen
(22)
Adult
(21)
Treatment Outcome
(20)
Severity Of Illness Index
(19)
Antibodies, Monoclonal - Therapeutic Use
(15)
Double-Blind Method
(15)
Aged
(13)
Antibodies, Monoclonal - Adverse Effects
(13)
Etanercept
(12)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)

Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Guidelines of care for the management of psoriasis and psoriatic arthritis

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis

Humanized anti–IFN-γ (HuZAF) in the treatment of psoriasis

Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis

Research gaps in psoriasis: Opportunities for future studies

Integrated safety analysis: Short- and long-term safety profiles of etanercept in patients with psoriasis

Clinical Goals and Barriers to Effective Psoriasis Care

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics

Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2)

Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities

Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies

Wolf’s isotopic response of lichen planus following contact dermatitis

Joint AAD–NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures

Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy

Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients

Guidelines of care for the management of psoriasis and psoriatic arthritis Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions

Guidelines of care for the management of psoriasis and psoriatic arthritis Section 2. Psoriatic arthritis : Overview and guidelines of care for treatment with an emphasis on the biologics

Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis

Aktive Filter

Suchergebnisse filtern